Positive safety and tolerability profile of NAV-240 in Phase 1a study support further development Phase 1b study fully enrolled and data expected in early 2026 Further clinical development of NAV-240 ...

LAS VEGAS (FOX5) — Las Vegas Metropolitan Police Department officials announced “phase two” of the department’s Drone First Responder Program, which will include new “sky ports” and remotely piloted ...

GE Aerospace has appointed veteran engineer Craig Higgins as chief mechanic and architect for the Open Fan engine project, marking an increased focus on the producibility, durability and maintenance ...

COQUITLAM, BC / ACCESS Newswire / September 17, 2025 / Grid Battery Metals Inc. (the "Company" or "Grid") (TSXV:CELL)(OTCQB:EVKRF)(FRA:NMK2) is pleased to announce that the first phase of the fall ...

Thunder Bay, Ontario--(Newsfile Corp. - September 8, 2025) - Thunder Gold Corp. (TSXV: TGOL) (FSE: Z25) (OTCQB: TGOLF) ("Thunder Gold" or the "Company") is pleased to announce complete results for the ...

“Southeast Sports+” brings you coverage, analysis, and talk about Southeastern Conference Athletics and the big sports stories making news today. WKRG News 5‘s Simone Eli and Gerhard Mathangani host ...

Ero Copper (ERO) announces the remaining assay results from its 28,000-meter Phase 1 drill program at the Furnas Copper-Gold Project, located in the Carajas Mineral Province in Para State, Brazil.

WASHINGTON — NASA expects to spend up to $1.5 billion to support at least two companies to demonstrate crew-tended space stations as part of the agency’s revised approach to transition from the ...

Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a potential first-in-class investigational oral orexin receptor ...

SINGAPORE & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861) 1, ...

Medicxi Ventures’ asset-focused investment model has scored another hit, in a $450 million deal with Servier SA, for KER-0193, an oral small molecule that is ready for phase II development in the ...